Summary

The global benign prostatic hyperplasia treatment market size reached US$ 11.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.
The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type.
Breakup by Treatment Type:
• Drug Class
o Alpha-Blockers
o 5-Alpha-reductase Inhibitors (5-ARIs)
o Phosphodiesterase-5 Enzyme Inhibitors
o Others
• Minimally Invasive Surgeries
o Transurethral Resection of the Prostate (TURP)
o Transurethral Incision of the Prostate (TUIP)
o Transurethral Microwave Thermotherapy (TUMT)
o Robotic Surgeries
o Prostatic Urethral Lifts
o Others
• Laser Therapy
• Others

Breakup by Region:
• North America
o United States
o Canada
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
• Latin America
o Brazil
o Mexico
o Others
• Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:
• How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the treatment type?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players?
• What is the degree of competition in the industry?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Benign Prostatic Hyperplasia Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Drug Class
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Alpha-Blockers
6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
6.1.2.4 Others
6.1.3 Market Forecast
6.2 Minimally Invasive Surgeries
6.2.1 Market Trends
6.2.2 Major Types
6.2.2.1 Transurethral Resection of the Prostate (TURP)
6.2.2.2 Transurethral Incision of the Prostate (TUIP)
6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
6.2.2.4 Robotic Surgeries
6.2.2.5 Prostatic Urethral Lifts
6.2.2.6 Others
6.2.3 Market Forecast
6.3 Laser Therapy
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Region
7.1 North America
7.1.1 United States
7.1.1.1 Market Trends
7.1.1.2 Market Forecast
7.1.2 Canada
7.1.2.1 Market Trends
7.1.2.2 Market Forecast
7.2 Asia Pacific
7.2.1 China
7.2.1.1 Market Trends
7.2.1.2 Market Forecast
7.2.2 Japan
7.2.2.1 Market Trends
7.2.2.2 Market Forecast
7.2.3 India
7.2.3.1 Market Trends
7.2.3.2 Market Forecast
7.2.4 South Korea
7.2.4.1 Market Trends
7.2.4.2 Market Forecast
7.2.5 Australia
7.2.5.1 Market Trends
7.2.5.2 Market Forecast
7.2.6 Indonesia
7.2.6.1 Market Trends
7.2.6.2 Market Forecast
7.2.7 Others
7.2.7.1 Market Trends
7.2.7.2 Market Forecast
7.3 Europe
7.3.1 Germany
7.3.1.1 Market Trends
7.3.1.2 Market Forecast
7.3.2 France
7.3.2.1 Market Trends
7.3.2.2 Market Forecast
7.3.3 United Kingdom
7.3.3.1 Market Trends
7.3.3.2 Market Forecast
7.3.4 Italy
7.3.4.1 Market Trends
7.3.4.2 Market Forecast
7.3.5 Spain
7.3.5.1 Market Trends
7.3.5.2 Market Forecast
7.3.6 Russia
7.3.6.1 Market Trends
7.3.6.2 Market Forecast
7.3.7 Others
7.3.7.1 Market Trends
7.3.7.2 Market Forecast
7.4 Latin America
7.4.1 Brazil
7.4.1.1 Market Trends
7.4.1.2 Market Forecast
7.4.2 Mexico
7.4.2.1 Market Trends
7.4.2.2 Market Forecast
7.4.3 Others
7.4.3.1 Market Trends
7.4.3.2 Market Forecast
7.5 Middle East and Africa
7.5.1 Market Trends
7.5.2 Market Breakup by Country
7.5.3 Market Forecast
8 SWOT Analysis
8.1 Overview
8.2 Strengths
8.3 Weaknesses
8.4 Opportunities
8.5 Threats
9 Value Chain Analysis
10 Porters Five Forces Analysis
10.1 Overview
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Degree of Competition
10.5 Threat of New Entrants
10.6 Threat of Substitutes
11 Price Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Profiles of Key Players
12.3.1 Abbott Laboratories
12.3.1.1 Company Overview
12.3.1.2 Product Portfolio
12.3.1.3 Financials
12.3.1.4 SWOT Analysis
12.3.2 Allergan plc (AbbVie Inc.)
12.3.2.1 Company Overview
12.3.2.2 Product Portfolio
12.3.2.3 Financials
12.3.2.4 SWOT Analysis
12.3.3 Asahi Kasei Corporation
12.3.3.1 Company Overview
12.3.3.2 Product Portfolio
12.3.3.3 Financials
12.3.3.4 SWOT Analysis
12.3.4 Astellas Pharma Inc.
12.3.4.1 Company Overview
12.3.4.2 Product Portfolio
12.3.4.3 Financials
12.3.4.4 SWOT Analysis
12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
12.3.5.1 Company Overview
12.3.5.2 Product Portfolio
12.3.5.3 SWOT Analysis
12.3.6 Boston Scientific Corporation
12.3.6.1 Company Overview
12.3.6.2 Product Portfolio
12.3.6.3 Financials
12.3.6.4 SWOT Analysis
12.3.7 GlaxoSmithKline Plc
12.3.7.1 Company Overview
12.3.7.2 Product Portfolio
12.3.7.3 Financials
12.3.7.4 SWOT Analysis
12.3.8 Pfizer Inc.
12.3.8.1 Company Overview
12.3.8.2 Product Portfolio
12.3.8.3 Financials
12.3.8.4 SWOT Analysis
12.3.9 Sanofi S.A.
12.3.9.1 Company Overview
12.3.9.2 Product Portfolio
12.3.9.3 Financials
12.3.9.4 SWOT Analysis
12.3.10 Teva Pharmaceutical Industries Ltd.
12.3.10.1 Company Overview
12.3.10.2 Product Portfolio
12.3.10.3 Financials
12.3.10.4 SWOT Analysis
List of Figures
Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2023
Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2023
Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million US$), 2018 & 2023
Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2023
Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players